Follow Us TR

News Details

Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 RELIEF Study of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) for Management of Fibromyalgia

About Tonix Pharmaceuticals Holding Corp.
  • NASDAQ: $TNXP
  • Notified: $0.81
  • 07:01 EDT

Price Chart